MI Cancer Seek
Caris Life Sciences · Decision date Nov 5, 2024
What did the FDA approve?
The FDA decision dated 2024-11-05 is an approval (APPR) for MI Cancer Seek, submitted by Caris Life Sciences under PMA number P240010. No supplement type or supplement reason is provided, so the record does not establish this as a supplement to an earlier PMA; it describes the device scope directly. MI Cancer Seek is a next-generation sequencing-based in vitro diagnostic using total nucleic acid from formalin-fixed paraffin-embedded tumor tissue to detect single nucleotide variants and insertions and deletions in 228 genes, microsatellite instability, and tumor mutational burden in patients with previously diagnosed solid tumors, plus copy number amplification in one gene in patients with breast cancer.
The stated purpose is companion diagnostic use to identify patients who may benefit from the targeted therapies listed in Table 1, per approved therapeutic product labeling, and tumor mutational profiling by qualified healthcare professionals in accordance with professional oncology guidelines. The statement says genomic findings outside Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. This wording reports intended use; it does not itself demonstrate safety or clinical effectiveness. Table 1 is referenced but not reproduced in the supplied fields, and the specific gene for copy number amplification is unnamed, so those details are absent from the record.
FDA approval order statement
Approval order for MI Cancer Seek. MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 below, in accordance with the approved therapeutic product labeling (see approval order for Table 1).Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Nov 5, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240010
- Regulatory pathway
- Premarket approval application
- Applicant
- Caris Life Sciences
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Nov 5, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Caris Life Sciences
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240010 received
Application receipt date recorded by FDA.
P240010 · FDA decision
APPR
P240010/S007 · Related supplement
MI Cancer Seek
Timeline entries are records held by MedtechLedger for P240010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Caris Life Sciences
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4610 S. 44th Pl., Phoenix, AZ, 85040
Sources and methodology
- Original FDA record: P240010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



